Comparison · NCT00952705-sae
Q/LAIV-BFS (MEDI8662) vs All FluMist: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Q/LAIV-BFS (MEDI8662) vs All FluMist: serious adverse events. Trial comparisons, record NCT00952705-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00952705-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0125 | 0.0076 | 0.0206 | wilson | |
| Risk in group 2 | 0.00336 | 0.000921 | 0.0122 | wilson | |
| Risk difference, group 1 minus group 2 | 0.00917 | -0.000913 | 0.0176 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 3.73 | 0.856 | 16.3 | log | |
| Odds ratio, group 1 over group 2 | 3.77 | 0.858 | 16.5 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Q/LAIV-BFS (MEDI8662) than on All FluMist | 109 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Q/LAIV-BFS (MEDI8662) | Q/LAIV-BFS (quadrivalent influenza vaccine) (MEDI8662) was supplied in the blow-fill-seal delivery system that delivers a nominal dose of 0.2 mL into a single nostril. Each dose contained 10\^7.0 ± 0.5 fluorescent focus units (FFU) of each of 4 cold-adapted, temperature-sensitive, attenuated, 6:2 reassortant influenza virus strains: A/H1N1 (A/South Dakota/6/2007), A/H3N2 (A/Uruguay/716/2007), B/Victoria (B/Malaysia/2506/2004), and B/Yamagata (B/Florida/4/2006). | 15 | 1,198 | EG000 |
| Group 2 | All FluMist | Data from both the FluMist/B/Yamagata arm and the FluMist/B/Victoria arm were combined. | 2 | 596 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Serious adverse events, Days 0-180 post dose; other adverse events, Days 0-28 post dose.
Source ClinicalTrials.gov
Trial
- Title
- A Study to Evaluate the Immunogenicity of Quadrivalent LAIV (MEDI8662) in Adults 18 to 49 Years of Age
- NCT number
- NCT00952705
- Phases
- PHASE3
- Conditions
- Healthy or Stable Underlying Chronic Medical Condition
- Interventions
- Q/LAIV-BFS (MEDI8662), FluMist/B/Yamagata, FluMist/B/Victoria
- Lead sponsor
- MedImmune LLC
- Results first posted
- 2012-01-13
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00952705?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00952705-sae